Latest News and Press Releases

SXTP posts Q1 2024 net product revenues increase of 515% year-over-year to $105.7 thousand in a Q1 earnings report released today.

SXTP received FDA comments on tafenoquine-babesiosis trial protocol; no major changes are needed. Trial planning and execution to proceed as planned.

Advanced Access Anywhere expands on AssistRx's digital intake strategies to automate enrollment at the point of pharmacy claim.

AssistRx, the advanced therapy initiation and patient solutions provider, has again earned the URAC accreditation for Mail Service Pharmacy.

60 Degrees Pharma (Nasdaq: SXTP) will sponsor a study using tafenoquine, an FDA-approved malaria drug, to treat canine babesiosis, a tick-borne disease.

Press Release Crossject reports financial results and business highlights for first half of 2023   Strong progress in bringing drugs for use in emergency situations towards the market ...

Communiqué de presse Crossject présente ses résultats financiers et faits marquants du premier semestre 2023   De solides avancées vers la mise sur le marché de médicaments dédiés aux situations...

ORLANDO, Fla., June 20, 2023 (GLOBE NEWSWIRE) -- AssistRx, the advanced therapy initiation and patient solutions provider, recently launched Advanced Gateway, a first-to-market single API...

ORLANDO, Fla., April 14, 2020 (GLOBE NEWSWIRE) -- AssistRx, the intelligent therapy initiation and patient support solutions provider, today announced the launch of a new website to reflect the...

ORLANDO, Fla. , Dec. 17, 2019 (GLOBE NEWSWIRE) -- Albertsons Companies Specialty Care is now using the AssistRx technology platform to give patients and providers quicker access to their specialty...